Patents by Inventor Nils Lonberg

Nils Lonberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220363774
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD-19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Application
    Filed: March 2, 2022
    Publication date: November 17, 2022
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • Patent number: 11408889
    Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: August 9, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Xi-Tao Wang, Olufemi A. Adelakun, Anne C. Lewin, Alan J. Korman, Mark J. Selby, Changyu Wang, Haichun Huang, Karla A. Henning, Nils Lonberg, Mohan Srinivasan, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Susan Chien-Szu Wong, Huiming Li
  • Patent number: 11401328
    Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: August 2, 2022
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
  • Patent number: 11384363
    Abstract: The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: July 12, 2022
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Daniel K. Rohrer, Amelia N. Black, Nils Lonberg
  • Publication number: 20220185907
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD-19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 16, 2022
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • Publication number: 20220185892
    Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
    Type: Application
    Filed: February 28, 2022
    Publication date: June 16, 2022
    Inventors: Alan J. KORMAN, Nils LONBERG, David J. FONTANA, Andres A. GUTIERREZ, Mark J. SELBY, Katherine LEWIS
  • Publication number: 20220185906
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD-19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 16, 2022
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • Publication number: 20220185908
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD-19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Application
    Filed: March 2, 2022
    Publication date: June 16, 2022
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • Publication number: 20220175921
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Guodong CHEN, Richard Y. HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan Chien-Szu WONG, Huiming LI, Bryan C. BARNHART, Aaron P. YAMNIUK, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
  • Patent number: 11352440
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: June 7, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
  • Patent number: 11345752
    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 31, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nils Lonberg, Mohan Srinivasan
  • Patent number: 11299551
    Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: April 12, 2022
    Assignee: Biograph 55, Inc.
    Inventors: Leonard Presta, Paul Tumeh, Nils Lonberg, Omar Duramad
  • Patent number: 11274152
    Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: March 15, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan J. Korman, Nils Lonberg, David J. Fontana, Andres A. Gutierrez, Mark J. Selby, Katherine Lewis
  • Patent number: 11213586
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 4, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Haichun Huang, Susan Chien-Szu Wong, Huiming Li, Bryan C. Barnhart, Aaron P. Yamniuk, Ming Lei, Liang Schweizer, Sandra V. Hatcher, Arvind Rajpal
  • Publication number: 20210340250
    Abstract: Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent.
    Type: Application
    Filed: May 30, 2018
    Publication date: November 4, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: Alan J. KORMAN, Nils LONBERG, Mark J. SELBY, Jeffrey JACKSON
  • Publication number: 20210283251
    Abstract: This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.
    Type: Application
    Filed: May 30, 2018
    Publication date: September 16, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: Lori S. BURTON, William YING, Nils LONBERG, Sudhir CHAKRAVARTHI, Pedro SMITH
  • Publication number: 20210269545
    Abstract: Targeting immunosuppressive B-cell populations with bispecific or multivalent targeting molecules presents a potential pathway for therapeutic intervention that effectively modulates the anti-tumor immune response to improve therapeutic outcomes. Accordingly, there remains a need for engineered antibody-based therapeutics that can effectively and selectively target immunosuppressive B-cell populations for the treatment of cancer. Provided are composite binding molecules that target immunosuppressive B cells.
    Type: Application
    Filed: April 13, 2021
    Publication date: September 2, 2021
    Inventors: Leonard PRESTA, Paul TUMEH, Nils LONBERG, Omar DURAMAD
  • Publication number: 20210261666
    Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-Ll positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.
    Type: Application
    Filed: May 30, 2018
    Publication date: August 26, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: James NOVOTNY, JR., Nils LONBERG, Cyrus HEDVAT, Raphael CLYNES, Darren LOCKE, John P. COGSWELL, Jeffrey JACKSON, Christopher HARBISON, Robin EDWARDS
  • Patent number: 11084881
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: August 10, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
  • Publication number: 20210009692
    Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
    Type: Application
    Filed: September 11, 2020
    Publication date: January 14, 2021
    Inventors: Alan J. KORMAN, Nils LONBERG, David J. FONTANA, Andres A. GUTIERREZ, Mark J. SELBY, Katherine LEWIS